Action 27. Mobilize their networks and work with communities to help build treatment literacy, generate demand, and expand access to ARVs among children.
Action 34. Increase efforts to share information on the roll-out of new paediatric formulations, including lessons learned.
2017 / 2018 TREATMENT
HIGH LEVEL DIALOGUES
Diagnostics for the Real World Ltd
Gilead Sciences, Inc.
Hetero Labs Ltd
Johnson & Johnson
Macleods Pharmaceutical Ltd
OraSure Technologies Inc.
Roche Diagnostics Intenational Ltd